Clinical Trials Logo

Filter by:
NCT ID: NCT01419964 Withdrawn - Vitiligo Clinical Trials

Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Start date: January 2012
Phase: Phase 3
Study type: Interventional

This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.

NCT ID: NCT01409408 Withdrawn - Hypertension Clinical Trials

Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Assess if aliskiren is capable of enhancing vascular stiffness and endothelial function and compare theses effects and renin activity and concentration to those obtained with a calcium channel blocker, amlodipine, in patients with diabetes mellitus type 2 and blood pressure not controlled by 100 mg per day of losartan.

NCT ID: NCT01402596 Withdrawn - Clinical trials for Traumatic Brain Injury

Evaluation of Pediatric Procedural Sedation With Rectal Chloral Hydrate or Intranasal Midazolam

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Thousands of children receive sedation for diagnostic and therapeutic interventions annually, and this number is expected to increase. Children are at higher risk for sedation-related complications than adults. In different scenarios, multiple drugs are used to achieve sedation, each one with particular adverse events that must be monitored and reported. Children that need CT scans for traumatic brain injuries often need sedation, without needing and IV line for that. Chloral hydrate is an hypnotic agent used since 1832 with low incidence of adverse events; however, despite its worldwide use, it's being abandoned due to bitter taste, long time of sedation onset, vomiting and mild sedation. Intranasal midazolam, on the other hand, produces high and fast concentrations on CSF with greater rates of success but probably with higher adverse events. There are no prospective studies with large series of patients using intranasal midazolam. The aim of this study is to determine if nasal midazolam is a safer approach and more effective sedative regimen when compared to rectal chloral hydrate to children undergoing CT scans.

NCT ID: NCT01394913 Withdrawn - Clinical trials for Rheumatoid Arthritis

Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis

Start date: August 2013
Phase: Phase 3
Study type: Interventional

This study is a comparison of safety and efficacy of two etanercept regimens (REUMATOCEPT® versus ENBREL®) for treatment of Rheumatoid Arthritis.

NCT ID: NCT01368679 Withdrawn - Clinical trials for Cardiovascular Diseases

A Clinical Study to Evaluate the Safety and Performance of the Modular AAA Stent-Graft System

Stent-Graft
Start date: n/a
Phase: Phase 3
Study type: Interventional

This is a prospective multicenter observational study with 20 patients to evaluate the performance of SCITECH stent for treatment of AAA. Will be enrolled the patient demographics, laboratory tests, medical history, clinical evaluation, physical examination, adverse events. The benefits and risks of the study should be explained before any specific test or procedure of the study. The written consent must be obtained from the patient. No action specifies the study should be performed while the patient has not signed the form of consent.

NCT ID: NCT01345084 Withdrawn - Clinical trials for Head and Neck Cancer

Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab

NICAP
Start date: November 2013
Phase: Phase 3
Study type: Interventional

Primary: to compare the overall survival defined as the time elapsed between the randomization date and death due to any cause, in both treatment groups. Secondary: to compare the progression-free survival, incidence of locoregional failure, site of the first recurrence/progression, objective response rate assessment, quality of life assessment and incidence of adverse events.

NCT ID: NCT01313702 Withdrawn - Clinical trials for Cardiovascular Disease

Single Pill to Avert Cardiovascular Events

SPACE
Start date: October 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether a polipill improved the compliance with treatment compared to usual care that use two or more drugs,in patients at high cardiovascular risk or previous cardiovascular disease.

NCT ID: NCT01308047 Withdrawn - Clinical trials for Fracture of Lower Limb

Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the non-inferiority between Heavy Levobupivacaine with Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine During Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.

NCT ID: NCT01305551 Withdrawn - Type 2 Diabetes Clinical Trials

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Start date: March 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and Metformin from a 5 mg Saxagliptin/500 mg Metformin extended release (XR) fixed dose combination (FDC) tablet relative to 5 mg Onglyza™ and 500 mg Glifage® XR (marketed in Brazil by Merck S.A.) tablets administered together in both the fasted and fed states.

NCT ID: NCT01303107 Withdrawn - Cesarean Delivery Clinical Trials

Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if the mixture of enantiomers of bupivacaine (bupivacaine S75:R25) dos not represent inferiority efficacy and safety compare to the racemic mixture of enantiomers of bupivacaine (bupivacaine S50:R50).